全髋与全膝关节置换术中的22修饰符:综合分析
这项回顾性研究评估了单中心2018年10月至2022年3月6869例初次全关节置换术中816例(11.9%)加用22修饰符的病例,其中221例(27.1%)获报销;肥胖是最常见理由但解剖变异报销成功率最高,联邦医疗保险报销可能性显著高于第三方保险或医疗补助。
要点
- 全关节置换术中22修饰符申请报销成功率低,816例中仅221例(27.1%)成功。
- 联邦医疗保险报销率显著高于第三方保险和医疗补助(69.6% vs 20.5% 和 6.9%,P < .0001)。
- 解剖变异理由报销成功率最高(35.7%),其次为术中并发症(29.7%)和肥胖(27.6%)。
核心结论
- 全关节置换术中22修饰符病例获得报销的可能性不大。
- 肥胖是大多数22修饰符申请的理由,但解剖变异理由的报销成功率最高。
- 联邦医疗保险相比第三方保险或医疗补助最有可能报销。
- 作者认为在给全关节置换术应用22修饰符时应考虑这些发现。
研究设计与样本
- 回顾性研究,评估单中心2018年10月至2022年3月所有在现行操作术语代码27130(全髋关节置换术)和27447(全膝关节置换术)中加用22修饰符的病例。
- 共完成6869例手术,其中识别出816例22修饰符病例(11.9%)。
- 评估手术报告、人口学资料、保险类型、计费信息和临床记录,使用t检验确定统计学显著性。
主要发现
- 816例中221例(27.1%)成功获得报销。
- 肥胖病例报销成功率为27.6%,术中并发症为29.7%,解剖变异为35.7%。
- 联邦医疗保险报销可能性显著高于第三方保险或医疗补助(69.6% vs 20.5% 和 6.9%,P < .0001)。
- 联邦医疗保险更可能为肥胖(76.6% vs 20.0% 和 5.2%)、解剖变异(77.3% vs 22.0%)和术中因素(66.6% vs 21.1% 和 1.7%)报销。
- 部分病例缺乏22修饰符申请理由,或未提交手术报告。
临床怎么用
- 作者认为在给全关节置换术应用22修饰符时应考虑这些发现。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The 22-modifier requests additional compensation for increased case complexity. Unfortunately, there is little to guide physicians on the application, which may increase successful reimbursement. We sought to evaluate various factors affecting reimbursement of the 22-modifier in primary total joint arthroplasty (TJA) and report which factors contributed to successful utilization. METHODS: In this retrospective study, all cases from a single practice where the 22-modifier was added to Current Procedural Terminology codes: 27130 (total hip arthroplasty) and 27447 (total knee arthroplasty) from October 2018 to March 2022 were evaluated. Out of the 6,869 total cases performed, 816 22-modifier cases were identified (11.9%). Operative reports, demographics, insurance type, billing information, and clinical records were assessed. T-tests were used to determine statistical significance. RESULTS: Of the 816 cases, 221 (27.1%) were successfully reimbursed. Cases justified 22-modifier application with obesity, anatomic variations, or intraoperative factors. Some cases lacked justification, or operative reports were not submitted. Reimbursement was successful for 27.6% of obesity cases, 29.7% of intraoperative complications, and 35.7% of anatomic variations. There was a significantly higher likelihood of Medicare reimbursement than third-party payers or Medicaid (69.6 versus 20.5 and 6.9%) (P < .0001). Additionally, Medicare was more likely to reimburse for obesity (76.6 versus 20.0, and 5.2%), anatomic variations (77.3 versus 22.0%), and intraoperative factors (66.6 versus 21.1, and 1.7%). CONCLUSIONS: Reimbursement for 22-modifier cases in TJA is unlikely. Obesity was cited for most 22-modifier justifications, but anatomic variation justification was successfully reimbursed most often. Medicare was most likely to reimburse compared to third-party payers or Medicaid. These findings should be considered when applying a 22-modifier to TJA procedures.
引用
- Comrie R, Pfeil AN, Huerta P, et al. The 22-Modifier in Total Hip and Knee Arthroplasty: A Comprehensive Analysis. J Arthroplasty. 2024. PMID: 38311299. doi:10.1016/j.arth.2024.01.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。